5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.52▲ | 0.52▲ | 0.52▲ | 0.54▼ | 0.57▼ |
MA10 | 0.52▲ | 0.52▲ | 0.52▲ | 0.54▼ | 0.55▼ |
MA20 | 0.52▲ | 0.52▲ | 0.53▼ | 0.56▼ | 0.58▼ |
MA50 | 0.52▲ | 0.53▼ | 0.54▼ | 0.54▼ | 0.80▼ |
MA100 | 0.53▲ | 0.53▼ | 0.55▼ | 0.58▼ | 2.10▼ |
MA200 | 0.54▼ | 0.54▼ | 0.53▲ | 0.74▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | 0.001▲ | 0.000▼ | -0.006▼ | 0.022▲ |
RSI | 55.818▲ | 52.403▲ | 49.342▼ | 47.028▼ | 42.023▼ |
STOCH | 59.751 | 35.748 | 41.352 | 26.533 | 49.238 |
WILL %R | 0.000▲ | -29.907 | -45.652 | -82.804▼ | -68.274 |
CCI | 149.297▲ | 28.651 | 34.054 | -59.377 | -39.979 |
Thursday, January 16, 2025 04:00 PM
Focusing on Neuroscience, Oncology, and Ophthalmology Pipelines FREMONT, CA - January 16, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company ...
|
Thursday, January 16, 2025 05:30 AM
NDAQ:ABVC) ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference ...
|
Tuesday, January 14, 2025 05:53 AM
EQS-News: ABVC BioPharma, Inc. / Key word (s): Financial AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees 14.01.2025 / 14:37 CET/CEST The issuer is ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
23/01/25 | 0.519 | 0.542 | 0.5136 | 0.5335 | 90,451 |
22/01/25 | 0.55 | 0.5559 | 0.52 | 0.52 | 111,146 |
21/01/25 | 0.53 | 0.56 | 0.528 | 0.5412 | 57,793 |
17/01/25 | 0.57 | 0.57 | 0.53 | 0.54 | 74,934 |
16/01/25 | 0.55 | 0.578 | 0.53 | 0.5511 | 114,094 |
15/01/25 | 0.52 | 0.563 | 0.52 | 0.545 | 79,500 |
14/01/25 | 0.5141 | 0.542 | 0.51 | 0.5157 | 131,833 |
13/01/25 | 0.5102 | 0.54 | 0.5102 | 0.53 | 114,417 |
10/01/25 | 0.55 | 0.5682 | 0.501 | 0.554 | 154,384 |
08/01/25 | 0.579 | 0.579 | 0.52 | 0.534 | 245,971 |
|
|
||||
|
|
||||
|
|